Start en underskriftsindsamling gennemse

To aloud OPDIVO in the UK not just Scotland sooner then a year.

af: Ieasha-rose Green
mottagare: pharmaphorum and BMS condemns

Advanced Squamous NSCLC Trial
In a clinical trial of 272 patients whose advanced squamous NSCLC had spread or grown after treatment with platinum-based chemotherapy, 135 were treated with OPDIVO, 137 were treated with chemotherapy (docetaxel). OPDIVO was shown to reduce the risk of dying by 41% compared to chemotherapy (docetaxel). Half of the patients on OPDIVO were still alive at 9.2 months, compared to 6 months with chemotherapy (docetaxel). OPDIVO will not work for everyone. Individual results may vary

Skriv under

Se flere underskriftsindsamlinger:

Sundhed

JavaScript er deaktiveret på din computer. Vores websted fungerer muligvis ikke korrekt, hvis ikke JavaScript er aktiveret.

fortrolighedspolitik

ved at underskrive accepterer du Care2's vilkår for tjeneste
Du kan til enhver tid administrere dine e-mailabonnementer.

Har problemer med at underskrive dette? Giv os besked.

Care2

To aloud OPDIVO in the UK not just Scotland sooner then a year.